Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The U.S. Food and Drug Administration (FDA) recently issued an alert on the potential risk of non-convulsive status epilepticus associated with the use of cefepime, a broad spectrum fourth generation cephalosporin.

Cefepime: FDA Drug Safety Communication on Non-Convulsive Status Epilepticus Risk